From: Productivity at work and quality of life in patients with rheumatoid arthritis
Baseline characteristics N = 150 |  | At-work productivity loss | ||
---|---|---|---|---|
Univariate N = 150 | ||||
 | Mean (sd) | B | 95% CI | p-value |
Clinical factors | Â | Â | Â | Â |
DAS score 28 joints | 2.70 (1.23) | 0.57 | 0.20; 0.94 | <0.01 |
- Swollen joints | 1.01 (2.01) | 0.19c | -0.04; 0.41 | 0.10 |
- Tender joints | 2.11 (3.10) | 0.14c | -0.01; 0.28 | 0.06 |
- ESR | 12.8 (13.0) | 0.03c | -0.004; 0.06 | 0.09 |
- VAS general health (0-100b) | 34.5 (22.5) | 0.03c | 0.01; 0.05 | 0.01 |
Number of DMARDS used since diagnosis | 2.13 (1.05) | 0.29 | -0.15; 0.72 | 0.19 |
Number of DMARDS used during last year | 1.10 (0.70) | 0.19 | -0.49; 0.87 | 0.58 |
Biological therapeutic used since diagnosis; yes | 47.3a | 0.86 | -0.05; 1.77 | 0.06 |
Biological therapeutic used during last year; yes | 34.5a | 0.34 | -0.62; 1.31 | 0.48 |
RF positive | 61.7a | 0.08 | -0.86; 1.02 | 0.87 |
aCCP positive | 65.1a | 0.13 | -0.81; 1.07 | 0.79 |
DAS: Disease Activity Score; ESR: Erythrocyte Sedimentation Rate; VAS: Visual Analogue Scale; DMARD: Disease-modifying Antirheumatic Drug; RF: Rheumatoid Factor; aCCP: Anti-cyclic Citrullinated Peptide Antibodies. |